Market access is about aligning internal strategies with external realities that often change without warning and at a frequency likely not experienced by other biopharma executive roles.

President Trump has reportedly selected White House Domestic Policy Council deputy director Heidi Overton as his nominee for ...

Spherix's VP of market access discusses how the IRA's maximum fair price is reshaping payer strategy, formulary design, and patient out-of-pocket costs far beyond negotiated drugs.

Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy ...

Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the ...

Lewis W. Coopersmith is an associate professor at Rider University and vice-president of Health Products Research.

The 340B spread mechanism permits covered entities to retain the difference between discounted acquisition cost and commercial or Medicare reimbursement, incentivizing revenue capture rather than ...

Exclusive ex-China rights extend to up to 10 partnered biosimilar programs, positioning Sandoz to shape development and registration strategy using early commercial and market-access input. Financial ...

Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not ...

Capital continues to flow toward clinical-stage and platform biotech companies, with a wave of new deals, partnerships, and ...

Pharmaceutical Executive releases its 2026 Top 50 company rankings, FDA grants Bristol Myers Squibb's Zenbexus accelerated ...

A changing of the guard atop Pharm Exec’s latest listing of the top biopharma Rx revenue producers reflects an industry being remade in real time, becoming as much a map of franchise quality and ...